The Experts below are selected from a list of 228 Experts worldwide ranked by ideXlab platform

J Gordon Millichap - One of the best experts on this subject based on the ideXlab platform.

Maureen Gartner - One of the best experts on this subject based on the ideXlab platform.

  • lesionectomy versus electrophysiologically guided resection for temporal lobe tumors manifesting with Complex Partial Seizures
    Journal of Neurosurgery, 1995
    Co-Authors: Rashid Jooma, Michael Privitera, Maureen Gartner
    Abstract:

    ✓ Complex Partial Seizures associated with tumors and other mass lesions are readily diagnosed by modern imaging techniques but their optimum surgical treatment remains unresolved. Lesionectomy has been reported to produce seizure outcomes equal to outcomes after resection that ablates the epileptogenic cortex with the lesion. However, some evidence suggests that when the lesion is in the temporal lobe, simple excision of the tumor or lesion more often fails to control Seizures. After retrospectively reviewing the records of 30 patients with Complex Partial Seizures and temporal lobe tumors who underwent surgical treatment at the University of Cincinnati hospitals (1985–1992), the authors divided them into two groups: Group A (16 patients) underwent lesionectomy only and Group B (14 patients) received surgical treatment for Seizures with electroencephalographic delineation of the epileptogenic zone and resection of the lesion. Seizure control was best achieved in Group B patients with 13 (92.8%) seizure f...

Josemir W Sander - One of the best experts on this subject based on the ideXlab platform.

  • vigabatrin therapy for refractory Complex Partial Seizures review of major european trials
    Acta Neurologica Scandinavica, 2011
    Co-Authors: Elinor Benmenachem, Josemir W Sander
    Abstract:

    Ben-Menachem E, Sander JW. Vigabatrin therapy for refractory Complex Partial Seizures: review of major European trials. Acta Neurol Scand: 2011: 124 (Suppl. 192): 16–28. © 2011 John Wiley & Sons A/S. Complex Partial Seizures (CPS) are a form of localization-related Seizures associated with serious comorbidities and risks. CPS can be difficult to treat and may remain refractory to treatment with antiepileptic drugs (AEDs). Refractory CPS (rCPS) can be hazardous because of the potential for severe dysfunction and bodily harm, sometimes with fatal consequences. Control of seizure activity is critical to the clinical management of CPS. Vigabatrin is a unique AED approved in both Europe and the United States as adjunctive therapy for adult patients with rCPS who have responded inadequately to several alternative treatments. This review focuses on appropriately controlled studies of vigabatrin conducted in Europe. Several double-blind studies randomized those with rCPS to treatment with vigabatrin vs placebo, and two evaluated durability of response to long-term, open-label vigabatrin. Endpoints included seizure frequency, treatment satisfaction, and adverse events (AEs). Efficacy outcomes demonstrated that vigabatrin add-on therapy significantly reduced the frequency of Seizures. Long-term studies indicated durability of response and tolerability of vigabatrin therapy for up to several years. Treatment satisfaction data indicated a preference for vigabatrin vs placebo for both physicians and study participants. Vigabatrin was well-tolerated with generally mild AEs considered common to AEDs. Vision effects were not formally monitored in these studies. In European trials, vigabatrin was efficacious as adjunctive therapy for rCPS.

E Faught - One of the best experts on this subject based on the ideXlab platform.

  • vigabatrin therapy for refractory Complex Partial Seizures review of clinical trial experience in the united states
    Acta Neurologica Scandinavica, 2011
    Co-Authors: E Faught
    Abstract:

    Faught E. Vigabatrin therapy for refractory Complex Partial Seizures: review of clinical trial experience in the United States. Acta Neurol Scand: 2011: 124 (Suppl. 192): 29–35. © 2011 John Wiley & Sons A/S. Vigabatrin is an antiepileptic drug used in more than 50 countries as adjunctive therapy for the treatment of refractory Complex Partial Seizures (rCPS) in adults. First approved in the United Kingdom in 1989, vigabatrin was approved for use in the United States by the Food and Drug Administration in 2009. Although most clinical trials of vigabatrin have been conducted in Europe, three major trials, including two pivotal trials, were conducted in the United States. These trials have demonstrated efficacy and tolerability findings similar to those observed from the European trials. Results of the US trials have demonstrated vigabatrin to be an effective and generally well-tolerated therapy for rCPS in adults, with an optimal dosage of 3 g/day for most patients, and an onset of response generally within 2 weeks. This review focuses on the design and results of the three major US trials of vigabatrin in adults with rCPS.

I Bone - One of the best experts on this subject based on the ideXlab platform.

  • ictal postictal spect in the pre surgical localisation of Complex Partial Seizures
    Journal of Neurology Neurosurgery and Psychiatry, 1993
    Co-Authors: Roderick Duncan, J Patterson, Richard C Roberts, D M Hadley, I Bone
    Abstract:

    Single photon emission computed tomography (SPECT) used in conjunction with HM-PAO (Ceretec-Amersham International) was used to image regional cerebral blood flow (rCBF) in 28 patients with medically intractable Complex Partial Seizures during or soon after a seizure, and interictally. Changes from interictal rCBF were seen in 26/28 (93%) patients. The main findings were; 1) During the seizure--hyperperfusion of the whole temporal lobe; 2) Up to 2m postically--hyperperfusion of the hippocampus with hypoperfusion of lateral temporal structures; 3) From 2-15m postically--hypoperfusion of the whole temporal lobe. When compared with EEG and MRI data, correct localisation to one temporal lobe was obtained in 23 patients. In one further patient bilateral temporal foci, and in a further two patients frontal foci, were correctly identified. There were no disagreements between EEG and SPECT localisation. Temporal lobe surgery was successful (by the criterion of at least 90% reduction in seizure frequency) in all but one of the 23 patients operated on. It is concluded that ictal/postictal SPECT is a reliable technique for the presurgical localisation of Complex Partial Seizures. The data indicate a likely sequence of changes in rCBF during and after Complex Partial Seizures of temporal lobe origin.

  • Ictal/postictal SPECT in the pre-surgical localisation of Complex Partial Seizures.
    Journal of Neurology Neurosurgery and Psychiatry, 1993
    Co-Authors: Roderick Duncan, J Patterson, Richard C Roberts, D M Hadley, I Bone
    Abstract:

    Single photon emission computed tomography (SPECT) used in conjunction with HM-PAO (Ceretec-Amersham International) was used to image regional cerebral blood flow (rCBF) in 28 patients with medically intractable Complex Partial Seizures during or soon after a seizure, and interictally. Changes from interictal rCBF were seen in 26/28 (93%) patients. The main findings were; 1) During the seizure--hyperperfusion of the whole temporal lobe; 2) Up to 2m postically--hyperperfusion of the hippocampus with hypoperfusion of lateral temporal structures; 3) From 2-15m postically--hypoperfusion of the whole temporal lobe. When compared with EEG and MRI data, correct localisation to one temporal lobe was obtained in 23 patients. In one further patient bilateral temporal foci, and in a further two patients frontal foci, were correctly identified. There were no disagreements between EEG and SPECT localisation. Temporal lobe surgery was successful (by the criterion of at least 90% reduction in seizure frequency) in all but one of the 23 patients operated on. It is concluded that ictal/postictal SPECT is a reliable technique for the presurgical localisation of Complex Partial Seizures. The data indicate a likely sequence of changes in rCBF during and after Complex Partial Seizures of temporal lobe origin.